CN110337449A - 抗pd-l1抗体及其应用 - Google Patents

抗pd-l1抗体及其应用 Download PDF

Info

Publication number
CN110337449A
CN110337449A CN201880011694.5A CN201880011694A CN110337449A CN 110337449 A CN110337449 A CN 110337449A CN 201880011694 A CN201880011694 A CN 201880011694A CN 110337449 A CN110337449 A CN 110337449A
Authority
CN
China
Prior art keywords
seq
antibody
cell
variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880011694.5A
Other languages
English (en)
Other versions
CN110337449B (zh
Inventor
武海
姚盛
周岳华
姚剑
蒙丹
冯辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CN110337449A publication Critical patent/CN110337449A/zh
Application granted granted Critical
Publication of CN110337449B publication Critical patent/CN110337449B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种以高亲和力与PD‑L1特异性结合的抗体或其功能性片段，编码上述抗体或其功能性片段的核酸分子，用于表达上述抗体或其功能性片段的表达载体和宿主细胞，以及上述抗体或其功能性片段的生产方法。一种包含上述抗体或其功能性片段的免疫缀合物以及药物组合物，以及使用上述抗体或其功能性片段增强T细胞的功能以上调细胞介导的免疫应答用于治疗T细胞功能失调性疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201880011694.5A 2017-02-21 2018-02-13 抗pd-l1抗体及其应用 Active CN110337449B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100936316 2017-02-21
CN201710093631.6A CN108456251A (zh) 2017-02-21 2017-02-21 抗pd-l1抗体及其应用
PCT/CN2018/076669 WO2018153320A1 (zh) 2017-02-21 2018-02-13 抗pd-l1抗体及其应用

Publications (2)

Publication Number Publication Date
CN110337449A true CN110337449A (zh) 2019-10-15
CN110337449B CN110337449B (zh) 2023-08-15

Family

ID=63221724

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710093631.6A Pending CN108456251A (zh) 2017-02-21 2017-02-21 抗pd-l1抗体及其应用
CN201880011694.5A Active CN110337449B (zh) 2017-02-21 2018-02-13 抗pd-l1抗体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710093631.6A Pending CN108456251A (zh) 2017-02-21 2017-02-21 抗pd-l1抗体及其应用

Country Status (7)

Country Link
US (1) US11267890B2 (zh)
EP (1) EP3587453A4 (zh)
JP (1) JP7361610B2 (zh)
KR (1) KR20190141128A (zh)
CN (2) CN108456251A (zh)
BR (1) BR112019017023A2 (zh)
WO (1) WO2018153320A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021136489A1 (zh) * 2019-12-31 2021-07-08 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
CN113087796A (zh) * 2021-04-02 2021-07-09 河南省肿瘤医院 一种抗pd-l1抗体及其应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CN109053891B (zh) * 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
CN110423277B (zh) * 2019-03-21 2022-09-06 南京东极医药科技有限公司 Pd-1的纳米抗体及其临床应用
CN113677709A (zh) * 2019-04-11 2021-11-19 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
CN110156895B (zh) * 2019-05-30 2020-11-20 上海甲贝生物医药技术股份有限公司 一种抗pd-l1抗体或其功能性片段及其用途
EP4001308A4 (en) 2019-07-15 2023-08-23 Shanghai Junshi Biosciences Co., Ltd. ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
CN112759647B (zh) * 2019-10-21 2024-03-26 上海宏成药业有限公司 一种抗pd-l1的抗体及其制药用途
CN112745391B (zh) * 2019-10-30 2022-11-22 三优生物医药(上海)有限公司 Pd-l1结合分子
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
CN116323658A (zh) * 2020-09-28 2023-06-23 上海君实生物医药科技股份有限公司 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
CN113413460A (zh) * 2021-08-10 2021-09-21 中山大学·深圳 Traf6抑制剂在制备黑色素瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2011066389A1 (en) * 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
RS61033B1 (sr) * 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2956399A1 (en) * 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
BR112017007379A2 (pt) * 2014-10-14 2017-12-19 Dana Farber Cancer Inst Inc moléculas de anticorpo para pd-l1 e usos das mesmas
CN105669864B (zh) 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 抗人程序性死亡受体1抗体及其制备方法和用途
CN106065031A (zh) 2016-01-14 2016-11-02 苏州金唯智生物科技有限公司 基于杂交瘤技术和高通量测序的抗体发现方法
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2011066389A1 (en) * 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021136489A1 (zh) * 2019-12-31 2021-07-08 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
CN113087796A (zh) * 2021-04-02 2021-07-09 河南省肿瘤医院 一种抗pd-l1抗体及其应用

Also Published As

Publication number Publication date
JP2020508079A (ja) 2020-03-19
CN110337449B (zh) 2023-08-15
JP7361610B2 (ja) 2023-10-16
US20190367618A1 (en) 2019-12-05
US11267890B2 (en) 2022-03-08
WO2018153320A1 (zh) 2018-08-30
EP3587453A4 (en) 2021-07-07
BR112019017023A2 (pt) 2020-04-14
KR20190141128A (ko) 2019-12-23
EP3587453A1 (en) 2020-01-01
CN108456251A (zh) 2018-08-28

Similar Documents

Publication Publication Date Title
CN110337449A (zh) 抗pd-l1抗体及其应用
CN104479018B (zh) 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US20200325236A1 (en) Agonistic 4-1bb monoclonal antibody
KR20200105849A (ko) 항-tigit 항체 및 치료제 및 진단제로서 이의 용도
CN106939049B (zh) 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
CN106102774A (zh) 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
CN111196852A (zh) 抗tigit抗体及其用途
KR20180116215A (ko) 암의 치료에 이용하기 위한 세포상해 유도 치료제
CN105899535A (zh) 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
CN108699124A (zh) 靶向表皮生长因子受体变体iii的嵌合抗原受体
CN105934253A (zh) 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
CN102131828A (zh) 针对人程序性死亡受体pd-1的抗体
US11236167B2 (en) Monoclonal antibody to PD-L1
WO2019141092A1 (zh) 抗lag-3抗体及其用途
US20240002503A1 (en) Novel anti-lilrb2 antibodies and derivative products
US20220403022A1 (en) Anti-TIGIT Antibodies and Uses Thereof
CN115812081A (zh) 抗ctla-4抗体及其用途
WO2023046113A1 (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
KR102679554B1 (ko) Pd-l1에 대한 단일클론 항체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013327

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant